Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXAS1 | P24557 | 7/20 | 0.77 |
| ▸ | HRH1 | P35367 | 2/20 | 0.65 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | RECQL | P46063 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.53 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.50 |
| ▸ | FAAH | O00519 | 1/20 | 0.49 |
| ▸ | CES1 | P23141 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18248629 | 1.00 | TBXAS1 (0.77) | TBXAS1HRH1CYP2A6TDP1L3MBTL1 | |
| SCHEMBL10772829 | 1.00 | TBXAS1 (0.77) | TBXAS1HRH1CYP2A6TDP1L3MBTL1 | |
| SCHEMBL4304368 | 0.98 | TBXAS1 (0.76) | TBXAS1HRH1CYP2A6TDP1L3MBTL1 | |
| SCHEMBL933853 | 0.93 | TBXAS1 (0.68) | TBXAS1HRH1CYP2A6TDP1L3MBTL1 | |
| SCHEMBL18248608 | 0.91 | TBXAS1 (0.65) | TBXAS1HRH1CYP2A6TDP1L3MBTL1 | |
| SCHEMBL18248504 | 0.91 | TBXAS1 (0.65) | TBXAS1HRH1CYP2A6TDP1L3MBTL1 | |
| SCHEMBL18248525 | 0.89 | TBXAS1 (0.62) | TBXAS1HRH1CYP2A6RECQLMAPT | |
| SCHEMBL83186 | 0.88 | RECQL (0.62) | TBXAS1HRH1CYP2A6RECQLCYP3A4 | |
| SCHEMBL7443753 | 0.87 | TBXAS1 (1.00) | TBXAS1HRH1CYP2A6TDP1L3MBTL1 | |
| SCHEMBL1009589 | 0.87 | TBXAS1 (1.00) | TBXAS1HRH1CYP2A6TDP1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2550965-B1 | Ceramide derivatives for treating polycystic kidney disease | GENZYME CORP (US) | 2019-01-16 | — | — | EP | disclosed |
| EP-2209473-B1 | METHOD OF TREATING POLYCYSTIC KIDNEY DISEASES WITH CERAMIDE DERIVATIVES | GENZYME CORP (US) | 2017-11-22 | — | — | EP | disclosed |
| EP-2320886-B1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITION FOR THE TREATMENT OF COLLAPSING GLOMERULOPATHY AND OTHER GLOMERULAR DISEASE | GENZYME CORP (US) | 2017-06-28 | — | — | EP | disclosed |
| EP-2594564-B1 | 2-acylaminopropanol-type glucosylceramide synthase inhibitors | GENZYME CORP (US) | 2016-09-28 | — | — | EP | disclosed |
| EP-2594562-B1 | 2-acylaminopropanol-type glucosylceramide synthase inhibitors | GENZYME CORP (US) | 2016-07-20 | — | — | EP | disclosed |
| EP-2594562-A2 | 2-acylaminopropanol-type glucosylceramide synthase inhibitors | Genzyme Corporation (US) | 2013-05-22 | — | — | EP | disclosed |
| EP-2594563-A2 | 2-acylaminopropanol-type glucosylceramide synthase inhibitors | Genzyme Corporation (US) | 2013-05-22 | — | — | EP | disclosed |
| EP-2594565-A2 | 2-acylaminopropanol-type glucosylceramide synthase inhibitors | Genzyme Corporation (US) | 2013-05-22 | — | — | EP | disclosed |
| EP-2594564-A2 | 2-acylaminopropanol-type glucosylceramide synthase inhibitors | Genzyme Corporation (US) | 2013-05-22 | — | — | EP | disclosed |